Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…
Glioma
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP…
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…
Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma.
Contract development and manufacturing organization Viralgen said it has scaled up production of Trogenix’s glioblastoma treatment TGX-007, as the companies move the gene therapy…
Each May marks Brain Tumor Awareness Month, with annual efforts to raise awareness about glioma and other types of cancer that affect the brain.
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the cell therapy BCB-276 as a potential treatment for diffuse intrinsic…
The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among people with gliomas, both proteins…
Personalized dosing and monitoring of drug levels may be necessary for children with low-grade glioma treated with Mekinist (trametinib), according to a study. The…
CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…
